<DOC>
	<DOCNO>NCT00951288</DOCNO>
	<brief_summary>This pilot interventional study whose aim determine effect dietary supplementation Crocus Sativus extract , Saffron , macular cone-mediated function patient early age-related macular degeneration ( AMD ) . Pre-clinical evidence ( Maccarone R , Di Marco S , Bisti S. Saffron supplement maintain morphology function exposure damage light mammalian retina . Invest Ophthalmol Vis Sci . 2008 Mar ; 49 ( 3 ) :1254-61 . ) indicate potential effectiveness Saffron retinal neuroprotectant animal model retinal degenerative disorders.The macular function test visual acuity macular cone-mediated electroretinogram ( focal electroretinogram , FERG ) accord standardize technique ( see citation ) .</brief_summary>
	<brief_title>Effect Saffron Supplementation Macular Cone-mediated Function Age-related Macular Degeneration</brief_title>
	<detailed_description>A group 30 AMD patient typical lesion ( drusen and/or retinal pigment epithelial defect ) relatively preserved central retinal function visual acuity enrol . AMD patient randomly divide two group : 1. placebo group [ n = 15 ) , take three month oral placebo ; 2 . Saffron group ( n = 15 ) , take Saffron oral treatment ( 20 mg/day ) three month . After three month placebo Saffron supplementation , patient test standard ophthalmic examination FERGs . Then , placebo Saffron vice-versa change patient cross-over design . After three month period placebo study drug supplementation , patient undergo standard ophthalmic examination , FERG . Throughout study , patient experimenter mask identity pill ( i.e . whether placebo study drug ) , whose identification key number keep sealed envelope open completion study . Therapeutic compliance test careful questioning , either two week treatment ( telephone interview ) end treatment period , well pill count . Main outcome measure study FERG amplitude phase .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Age &gt; 55 yrs Diagnosis Early , non exudative AMD Visual acuity 20/40 well Concomitant ocular systemic disorder may affect macular function Drugs may affect macular function</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>AMD</keyword>
	<keyword>Retinal Function</keyword>
	<keyword>Neuroprotection</keyword>
</DOC>